Newsfeeds - Spark Newswire

2 minute read

FDA
News

Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO

Today, 10:34 PM

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA") has affirmed the resubmission

LPCN

8 minute read

Penny Stocks

LPCN: Liver Biopsy Results

By Zacks Small Cap Research

Today, 10:34 PM

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

LPCN

1 minute read

HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $3.5

By Benzinga Newsdesk

Today, 10:34 PM

HC Wainwright & Co. analyst Oren Livnat maintains Lipocine (NASDAQ:LPCN) with a Buy and raises the price target from $2.5 to $3.5.

LPCN

1 minute read

Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial

By Vandana Singh

Today, 10:34 PM

Lipocine Inc (NASDAQ: LPCN) has

LPCN

4 minute read

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug

By Shanthi Rexaline

Today, 10:34 PM

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24)

AGEN

2 minute read

Lipocine Announces LPCN 1144 Met Non-Alcoholic Steatohepatitis Resolution Regulatory Endpoint In Phase 2 LiFT Study

By Bill Haddad

Today, 10:34 PM

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of

LPCN

1 minute read

Lipocine Shares See Volume; Zacks SCR Issues Report Titled ‘LPCN: New Candidate In Postpartum Depression’

By Benzinga Newsdesk

Today, 10:34 PM

https://scr.zacks.com/news/news-details/2021/LPCN-New-Candidate-in-Postpartum-Depression-article/default.aspx

LPCN

12 minute read

Penny Stocks

LPCN: New Candidate in Postpartum Depression

By Zacks Small Cap Research

Today, 10:34 PM

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

LPCN

1 minute read

Lipocine Q2 EPS $(0.08) Up From $(0.13) YoY

By Bill Haddad

Today, 10:34 PM

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share. This is a 38.46 percent increase over losses of $(0.13) per share from the same period last year.

LPCN

1 minute read

Legal
News

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine; Says Agreed To Settle All Outstanding Claims In Patent Infringement Lawsuit

By Benzinga Newsdesk

Today, 10:34 PM

Clarus and Lipocine (NASDAQ:LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine and to further resolve a patent interference between the parties. The action

LPCN